Peer Review History

Original SubmissionMarch 22, 2024
Decision Letter - Catherine Mounier, Editor

PONE-D-24-11620Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetesPLOS ONE

Dear Dr. Tourret,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. As raised by one reviewer, your observatioins on the effect of HFD is not very clear. You need at least to rerun some measurments on plasma TG and Cholesterol levels. It seems that your HFD is only for 4 weeks which is quite short in order to increase plasmatic TG and CHOL levels. You have to clearly justify the duration of the diet. In this situation, you cannot speak about  combine effects of HFD and IS.

Please submit your revised manuscript by Aug 31 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Catherine Mounier

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

 2. Thank you for stating the following financial disclosure:

“This work was funded by grants from the “Institut National de la Santé et de la Recherche Médicale”.

PG was supported by a grant “Année recherche” from “Assistance Publique – Hôpitaux de Paris AP-HP” in 2018.”

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: No

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: General comment

The values for total cholesterol and triglycerides presented in the manuscript are not appropriate for C56Bl6 mice (please see, DOI:10.1016/j.yexcr.2015.07.032) therefore you should re-run all the measurements and the statistical analyses, as well. Additionally, the data reported about the loss of BW indicate that the drug treatment was toxic for the mice. The Authors have included a sentence in this regards in the Discussion, but I believe that is not sufficient because they did not take into account this possibility.

Reviewer #2: Kidney transplantation requires a very thorough medical care post-surgery, including a specific diet and immunosuppressive therapy. Solid organ transplantation may lead to a change of the microbiota, with long-term consequences. This study is relevant both to the clinician in their daily practice, but also as a steppingstone for further studies, emphasizing the importance of all factors that may impact the metabolism of patients with kidney transplants. The acquirement of diabetes mellitus in such patients may have negative impact on quality of life, increasing morbidity and mortality.

The study is well conducted, clearly elaborated and explained in the manuscript, with appropriate statistical variables and analysis. The conclusion of the study is well supported, while the limitations have been clearly stated. All the necessary data and scientific findings have been made available in the manuscript. The text presents a high level of written clarity, with concise and clear ideas that provide the manuscript an optimal level of comprehension given the complex subject. The manuscript has been very well researched and referenced. The use of tables and figures are useful in increasing the understanding of the study. Particularly, Table 2 offers a concise summary of some of the aspects of the study and facilitates the readability of the manuscript.

After analyzing this manuscript, it can be considered for publication

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: Yes:  Elena Rezus

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 1

Editor

As raised by one reviewer, your observatioins on the effect of HFD is not very clear. You need at least to rerun some measurments on plasma TG and Cholesterol levels.

≫ The lipid values are in international units, mmol/L and not in mg/dL as stated on the graph. We apologize for this mistake but there is nothing wrong with the dosages that we performed. The graph now shows mmol/L.

It seems that your HFD is only for 4 weeks which is quite short in order to increase plasmatic TG and CHOL levels. You have to clearly justify the duration of the diet. In this situation, you cannot speak about combine effects of HFD and IS.

≫ Even though 4 weeks seems a short duration for the diet and the IST, we were able to observed clear-cut differences between groups. We chose this duration because new onset diabetes, weight gain, HBP, dyslipidemia are observed rapidly after KT as a consequence of IST. Also, we wanted to distinguish direct effects of diet and IST from long terms effect that maybe more related to weight gain and insulin resistance. We added a comment in the discussion.

Reviewer #1: General comment

The values for total cholesterol and triglycerides presented in the manuscript are not appropriate for C56Bl6 mice (please see, DOI:10.1016/j.yexcr.2015.07.032) therefore you should re-run all the measurements and the statistical analyses, as well.

≫ The lipid values are in international units, mmol/L and not in mg/dL as stated on the graph. We apologize for this mistake but there is nothing wrong with the dosages that we performed. The graph now shows mmol/L.

Additionally, the data reported about the loss of BW indicate that the drug treatment was toxic for the mice. The Authors have included a sentence in this regards in the Discussion, but I believe that is not sufficient because they did not take into account this possibility.

≫ We have added IS drug blood dosages in the discussion. Based on these dosages, we explain why we don’t think that IST were toxic in our experiments.

Attachments
Attachment
Submitted filename: Response to reviewers.docx
Decision Letter - Catherine Mounier, Editor

PONE-D-24-11620R1Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetesPLOS ONE

Dear Dr. Tourret,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Some comments raised by a reviewer needs to be adressed before final acceptance

Please submit your revised manuscript by Feb 21 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Catherine Mounier

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: Yes

Reviewer #3: No

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: Immunosuppressive treatment may play an important role in determining metabolic disfunction. Analyzing the combination of administered immunosuppressive therapeutic agents and high fat diet may provide information regarding the real-life experience of kidney transplant recipients. The subject of the study is relevant in clinical practice and original. The study presents research results that have not been published elsewhere. The methodology of the manuscript is well elaborated and explained, with a high level of the provided information and sufficient details, including statistical analysis. The information from this manuscript renders the process replicable. The conclusions are succinct, but present the main points of the study and are supported by the supplied data. The manuscript is logically structured, with an appropriate level of written clarity. The language is clear and concise, and uses suitable terminology given the context. Overall, the written comprehension of the manuscript is optimal. The research elaborated in the manuscript respects ethical standards regarding research on animal models and there are no elements that suggest transgression of research integrity. The results have been appropriately reported as per the required standards. The data concerning the study have been made fully available for analysis.

After analyzing this manuscript, it can be considered for publication.

Reviewer #3: This study showed that immunosuppressive therapy (IST) and high-fat diet (HFD) had some effects on gut microbiota and metabolism in mice. Here are some comments.

1. It could be improved by mentioning the specific immunosuppressive drugs used in the Abstract.

2. Note the units of insulin concentration , which should be consistent in the main text and Figure 1; The ordinate of Figure 5 is consistent with the main text.

3. LPS on line 247 is not equivalent to endotoxemia.

4. Specify the exact IST regimen used (prednisone, MMF, tacrolimus, etc.) and their doses.

5. Provide more details on the HFD composition.

6. Clarify the duration of the experiment and the time points for data collection.

7. Include more statistical details in figure legends.

8. A more in-depth discussion of the mechanisms by which IST and HFD may alter the gut microbiota and impact metabolism is necessary.

9. A discussion of the limitations of the study and potential areas for future research is necessary.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: Yes:  Elena Rezus

Reviewer #3: Yes:  Shijun Yue

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

Revision 2

Rebuttal letter

Reviewer #2:

After analyzing this manuscript, it can be considered for publication.

≫ Thank you very much

Reviewer #3: This study showed that immunosuppressive therapy (IST) and high-fat diet (HFD) had some effects on gut microbiota and metabolism in mice. Here are some comments.

1. It could be improved by mentioning the specific immunosuppressive drugs used in the Abstract.

≫ This precision was added to the revised manuscript

2. Note the units of insulin concentration, which should be consistent in the main text and Figure 1; The ordinate of Figure 5 is consistent with the main text.

≫ We apologize for this mistake and sincerely thank reviewer #3 for noticing it. The unit for insulin concentration is now consistent in the text and the figure: mUI/L.

3. LPS on line 247 is not equivalent to endotoxemia

≫ This was specified in the main text

4. Specify the exact IST regimen used (prednisone, MMF, tacrolimus, etc.) and their doses.

≫ We believe that this is already detailed in the paragraph “diets and treatment administration” of the material and methods section

5. Provide more details on the HFD composition

≫ This was added to the manuscript

6. Clarify the duration of the experiment and the time points for data collection

≫ This has been detailed in the material and methods section of the present revision

7. Include more statistical details in figure legends.

≫ The statistical details are described in the material and methods section and mostly comprises simple comparison tests. Adding them in the legend of each figure depends on the editorial choices of each journal and this was not asked to us in the first round of revisions.

8. A more in-depth discussion of the mechanisms by which IST and HFD may alter the gut microbiota and impact metabolism is necessary.

≫ “The mechanisms by which IST and HFD may alter the gut microbiota and impact metabolism” is a whole field of research per se and is way beyond the scope of the research presented here. Consequently, we believe that describing these mechanisms more in details would only be speculative as we did not investigate them, and wouldn’t add any scientific value to our work. However, we have already cited several works that specifically address these questions in the introduction and the discussion (see references 6-8, 13, and 31-34).

9. A discussion of the limitations of the study and potential areas for future research is necessary.

≫ This is the second round of revisions. A discussion of the limits of our work was already included in the original submission. It was extended in the first revision of the manuscript. Please tell us if you believe that a specific limitation has not been addressed in the last paragraph of the discussion.

As for future research, we specify in the manuscript that microbiota transfer experiments are underway. We believe that the goal of a scientific paper is more to describe what has been done than what is intended to be done.

Attachments
Attachment
Submitted filename: Rebuttal letter.docx
Decision Letter - Catherine Mounier, Editor

Immunosuppressive drugs and diet interact to modify the gut microbiota and cardiovascular risk factors, and to trigger diabetes

PONE-D-24-11620R2

Dear Dr. Tourret

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Catherine Mounier

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #3: Yes:  Shi-Jun Yue

**********

Formally Accepted
Acceptance Letter - Catherine Mounier, Editor

PONE-D-24-11620R2

PLOS ONE

Dear Dr. Tourret,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Catherine Mounier

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .